Metilação de DNA como potencial biomarcador da doença de Alzheimer by Almeida, João Carlos Moutinho de
   
 Universidade de Aveiro  
2013 
Secção Autónoma de Ciências da Saúde 
João Carlos Moutinho 
de Almeida 
 
Metilação de DNA como potencial biomarcador da 
Doença de Alzheimer  
DNA Methylation as a potential biomarker for 
Alzheimer Disease  
 
 
   
   
 Universidade de Aveiro  
2013 
Secção Autónoma de Ciências da Saúde 
João Carlos Moutinho 
de Almeida 
 
Metilação de DNA como potencial biomarcador da 
Doença de Alzheimer  
DNA Methylation as a potential biomarker for 
Alzheimer Disease 
  
 
Dissertação apresentada à Universidade de Aveiro para cumprimento dos 
requisitos necessários à obtenção do grau de Mestre em Biomedicina 
Molecular, realizada sob a orientação científica da Professora Doutora. Ana 
Gabriela da Silva Cavaleiro Henriques, Professora Auxiliar Convidada da 
Secção Autónoma de Ciências da Saúde da Universidade de Aveiro 
 
   
 
Este trabalho contou com o apoio do Centro 
de Biologia Celular (CBC) da Universidade de 
Aveiro, e é financiado por fundos FEDER 
através do Programa Operacional Factores de 
Competitividade-COMPETE e por Fundos 
nacionais da FCT no âmbito dos projetos 
PTDC/QUI-BIQ/101317/2008 e JPND-
BIOMARKAPD. 
   
  
 
 
 
Dedico em especial este trabalho aos meus avós, pessoas extraordinárias que 
me deram muito carinho, apoio e amor e que, apesar de já terem partido, estão 
sempre no meu coração... 
 
 
 
 
  
   
 
 
 
 
 
 
o júri   
 
presidente Professora Doutora Odete Abreu Beirão da Cruz e Silva 
 Professora Auxiliar C/Agregação da Secção Autónoma de Ciências da Saúde, Universidade 
de Aveiro 
 
  
 Doutor Luís Filipe da Silva Godinho 
Bolseiro de Pós-Doutoramento, Universidade de Aveiro 
  
 
 Professora Doutora Ana Gabriela da Silva Cavaleiro Henriques 
Professora Auxiliar Convidada da Secção Autónoma de Ciências da Saúde, Universidade 
de Aveiro 
  
  
 
  
  
 
  
  
 
  
 
 
 
  
   
  
 
agradecimentos 
 
Quero agradecer à Professora Doutora Odete Abreu Beirão da Cruz e Silva por me ter 
acolhido no laboratório, por me ter possibilitado a realização deste trabalho e por 
todas as suas sugestões pertinentes.  
Agradeço à minha orientadora, Professora Doutora Ana Gabriela da Silva Cavaleiro 
Henriques, pela forma como me tratou como pessoa, bem como, por todas as 
orientações dadas nas diferentes fases da tese, pelos ensinamentos, pelas correções, 
por todas críticas e pela motivação e apoio ao longo de todo este ano lectivo.  
Agradeço ao Centro de Biologia Celular e à FCT. 
Também queria agradecer a todos os elementos da equipa Gabi: Marta, Lili e Joana 
Oliveira por todo o apoio, ajuda e motivação. Um especial agradecimento para a Lili 
por toda a preciosa ajuda que me deu em todos os momentos deste trabalho. 
Aos meus colegas de mestrado, em especial, aos colegas de bancada de laboratório, 
Sónia, Patrícia, Ana Maria, Catarina e Luísa pelo companheirismo, apoio e ajuda. 
A todos os elementos do Laboratório de Neurociências, Mariana, Regina, Roberto, 
Pati, Filipa, Rocha... Um muito obrigado pelo bom ambiente e momentos divertidos. 
Aos meus pais quero agradecer toda a educação, confiança, apoio, amor e carinho 
transmitidos ao longo destes vários anos. Ao meu irmão pelo apoio prestado, pela 
compreensão e, claro, por estar sempre a torcer por mim.  
À Márcia queria agradecer por todo o carinho, apoio e dedicação todos os dias para 
que tudo me corra bem. Para ti um muito especial obrigado por me ajudares a crescer 
como pessoa e por me fazeres feliz…  
Aos meus amigos gostava de agradecer toda a amizade e companheirismo que 
ajudaram em todo o percurso. Obrigado!  
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
Metilação de DNA; regiões promotoras de genes; envelhecimento; Doença de 
Alzheimer; CpG; hipometilação 
 
resumo 
 
 
A metilação de DNA é, de todos os mecanismos epigenéticos, o mais 
estudado e consiste na adição de um grupo metil ao carbono da posição 5 do 
anel de uma citosina. A metilação da região promotora de genes está 
diretamente relacionada com silenciamento genético, podendo conduzir ao 
desenvolvimento de determinadas patologias, uma vez que genes importantes 
não são expressos devido a este mecanismo. Este mecanismo epigenético 
tem vindo a ser estudado a nível do cancro e, recentemente, tem adquirido 
alguma importância ao nível de doenças neurológicas, como a doença de 
Alzheimer (DA). O envelhecimento é o maior factor de risco para a DA e ao 
mesmo tempo está na base de muitas das alterações nos mecanismos 
epigenéticos. Como a patologia e etiologia da DA ainda não é completamente 
conhecida, alterações ao nível de mecanismos epigenéticos, como a metilação 
de DNA, podem ajudar a entender as alterações de expressão de genes nesta 
doença.  
Neste estudo, utilizaram-se amostras de pacientes com possível DA e 
controlos com idades semelhantes. O DNA genómico foi extraído de amostras 
de sangue e os níveis de metilação global foram avaliados por um ensaio de 
ELISA. Os pacientes apresentaram uma tendência para uma diminuição da 
metilação global (0,75%±0,29) relativamente aos controlos (0,86%±0,29). Os 
perfis de metilação dos genes envolvidos na DA, APP e ApoE, foram obtidos 
por Combine Bisulfite Restriction Analysis (COBRA), Methylation Sensitive - 
High Resolution Melting (MS-HRM) e Bisulfite Direct Sequencing (BDS). Para a 
região promotora do gene ApoE, não foram encontradas diferenças entre 
pacientes e controlos assim como a região promotora do gene APP não 
apresentou metilação através do método COBRA e MS-HRM. De igual modo, 
a região promotora do gene ApoE também não apresentou diferenças usando 
estas 2 técnicas. No entanto, a BDS evidenciou diferenças em locais CpGs 
específicos, mostrando que existe uma tendência para o aumento da metilação 
nos CpGs 1, 3 e 5; e para diminuição da metilação no CpG 6 dos pacientes 
relativamente aos indivíduos control. Este estudo permitiu verificar uma 
tendência para de diminuição da metilação global dos pacientes com possível 
DA relativamente aos controlos e também a existência de um possível padrão 
de metilação da região promotora do gene ApoE, que pode estar relacionado 
com a patologia da DA .  
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abstract 
 
DNA methylation is the major studied epigenetic mechanism and consists in 
the addiction of a methyl group to 5’ carbon position of the cytosine ring. 
Methylation of promoter gene regions are directly correlated with gene 
silencing, which can allow the development of certain diseases since relevant 
genes may be inhibited due to its promoter methylation; being that the opposite 
can also occur. This epigenetic mechanism has been linked to cancer and 
recently it is also being pointed to have an important role in neurological 
disorders, such as Alzheimer’s Disease (AD). Furthermore, aging is the major 
risk factor for AD, and also the process underlying many of the epigenetic 
alterations. As AD etiology and pathological development is not complete 
understood, alterations in epigenetic mechanisms like DNA methylation may 
underlie the basis of gene expression alterations. 
Hence, in this study, possible AD patients and age- and sex-matched controls 
were used. Genomic DNA was extracted from blood samples and the global 
methylation levels were determined using an ELISA-type assay, The possible 
AD patients exhibit lower methylation levels (0,75%±0,29) than age- and sex-
matched controls (0,86%±0,29). Gene specific methylation profiles of AD 
related genes, namely APP and ApoE, was carried out using Combine Bisulfite 
Restriction Analysis (COBRA), Methylation Sensitive-High Resolution Melting 
(MS-HRM) and Bisulfite Direct Sequencing. The APP promoter region did not 
reveal any methylation by COBRA and MS-HRM. For the ApoE promoter 
region evaluated no differences in the methylation levels could be detected 
between patients and controls using these two techniques. However, by 
sequencing analysis of this ApoE promoter region, differences arise in specific 
CpG sites, indicating a tendency for increased methylation of CpG1, CpG3 and 
CpG 5 and a decreased methylation of CpG6 in AD patients when compared 
with age- and sex-matched controls. In this study AD patients exhibited a 
tendency for lower global methylation levels when compared to control 
individuals and the ApoE promoter region exhibited a tendency for a pattern of 
methylation that maybe related to AD pathology. 
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1.1. EPIGENETICS 
Epigenetics can be defined as heritable changes in gene expression caused by 
modifications that do not involve alterations in deoxyribonucleic acid (DNA) sequence (1). 
Therefore, the term “epigenetic mechanisms” refers to the processes that modify gene expression 
without altering the genetic code itself. It includes covalent modifications of cytosine bases, 
namely DNA methylation; histones post-translational modifications, such as histones acetylation, 
phosphorylation or methylation; and changes in the nucleosomes positioning (2,3). These 
mechanisms play a key role in the regulation of many cellular processes, such as gene and 
microRNA expression, DNA-protein interactions, suppression of transposable element mobility, 
cellular differentiation, embryogenesis, X-chromosome inactivation and genomic imprinting (3). 
The epigenetic marks can persist during development and potentially be transmitted to 
offspring, allowing the formation of many different phenotypes from the same genomic material 
(4). For example, monozygotic twins, although having the same DNA genomic sequence, have 
different DNA methylation and histone modification profiles which may contribute to the 
differences in the penetrance of several diseases, such as cancer or autoimmune disorders (5). 
Besides this, epigenetics seems to be one of the key factors in cellular differentiation that allows, 
for example, the stem cells to develop into any type of cell (6). 
In the neurosciences field, the search for epigenetic modifications in the brain has pointed 
to the importance of this mechanism in development and disease, based on three evidences: the 
epigenome remains plastic throughout all periods of brain development and aging and that 
ongoing dynamic regulation occurs even in neurons and other postmitotic constituents of the 
brain (7–9); disordered chromatin organization and function have been pointed as playing key 
pathogenic roles in neurodevelopmental syndromes of early childhood and adult onset hereditary 
neurodegenerative disorders (10,11); and a variety of chromatin-modifying drugs had shown 
potential good results for a wide range of degenerative and functional disorders of nervous 
system (12–14). 
Epigenetic modifications can be divided into three groups: DNA methylation, histone 
modifications and nucleosome positioning. These events are always present in the cells and the 
epigenetic outcome results from their interactions and feedback mechanisms (3). 
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1.1.1. DNA methylation 
DNA methylation only occurs in the context of CpG dinucleotides, paired with the same 
sequence on the opposite DNA strand, and is the most widely studied epigenetic modification 
(3,15,16). The term “CpG” represents a cytosine (C) connected to a guanine (G) by a 
phosphodiester bond (3). The DNA strands can be methylated on both strands or only on one 
(hemimethylation), being the latter a transient stage during cell replication. The methylation 
patterns are copied between cell division by the DNA methyltransferase 1 (DNMT1), which only 
methylates DNA strand hemimethylated sites, leaving unmethylated the previous unmethylated 
DNA sites (15). The CpG dinucleotides tend to be found in regions called CpG islands (CGIs) that by 
definition are regions with more than 200 bases, with a G+C content more that 50% and a ratio of 
observed statistically expected CpG frequencies of at least 0,6 which can be calculated by this 
formula ((Num of CpG/(Num of C × Num of G)) × Total number of nucleotides in the sequence) 
(17). 
In mammals, most of cytosine methylation occurs in the context of CG dinucleotide (18). 
The enzymes family DNA methyltransferases (DNMTs) are responsible for catalyzing the 
transference of a methyl group, from S-adenosyl methionine, to the 5’ carbon position of the 
cystosine ring from DNA, resulting in its methylation (19). There are 5 members of the DNMT 
family but only DNMT1, DNMT3a and DNMT3b have methyltransferase activity (3). These 3 
enzymes can be divided in 2 classes according to their function: maintenance DNMT, such as 
DNMT1; and de novo DNMT, like DNMT3a and DNMT3b (3). For example, DNMT3a, along with its 
cofactor DNMT3-like, are active in sexual stem cells and are responsible for introducing DNA 
methylation in these cells during oogenesis or spermatogenesis. The new methylation occurs in 
CpG Islands contained in the promoter of imprinted genes and is responsible for their silencing, 
originating a long term epigenetic stability (20,21). On the other hand, DNMT1 can exist in two 
forms: DNMT1o, the oocyte form of DNMT1; and DNMT1s, the somatic form. The DNMT1o acts 
only in the first division after fertilization, by maintaining the methylation of differentially 
methylated imprinted genes regions, during pre-implantation development (22). In the 
subsequent divisions instead of DNMT1o, DNMT1s is active and maintain the methylation through 
embryonic and adult tissues cells division. DNA-methylation patterns are somatically heritable 
due to the action of DNMT1 which has a low error rate of maintaining methylation (approximately 
1% per division) (23).  
Although DNMTs are commonly divided in maintenance DNMTs and de novo DNMTs, this 
distinction not always apply with both class of enzymes being involved in de novo and 
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maintenance methylation (24). Unlike DNMT3b that encodes multiple variants via alternative 
splicing, DNMT3a has only two isoforms, Dnmt3a and Dnmt3a2, which have different DNA targets 
and functions in development (25). 
The methylation of DNA requires a component to provide a methyl group. This methyl 
group donor is not restricted to DNA methylation but also intervenes in other reactions that 
involve methylation, such as histone methylation. In all organisms, s-adenosylmethionine (SAM) is 
the primary methyl donor for processes that involves methylation of molecules (Figure 1) (26).  
 
Figure 1 - DNA Methylation cycle. The methionine is acquired through diet or from the folate metabolism and due to 
the action of methionine adenosyltransferase forms SAM. DNMTs transfer a methyl group from SAM to carbon in 
position 5 of cytosine ring, originating methylcytosine. As SAM loses a methyl group, another compound called S-
adenosylhomocysteine (SAH) is formed, whose high levels are responsible for inhibiting DNMTs activity. SAH is 
hydrolated by SAH hydrolase and forms homocysteine (HCY). HCY can be either subjected to transsulfuration, 
originating ultimately glutathione, an anti-oxidant agent from cystein; or undergo transmethylation, catalyzed by 
Methionine synthase, which consists in the transference of the methyl group to HCY, originating methionine. The 
transssulfuration and transmethylation pathways need adequate levels of vitamin B6 and vitamin B12 that act as 
cofactors preventing methionine from being converted back to SAH and HCY, respectively. Adapted from (27). 
DNA methylation leads to gene silencing mainly by two modes of action: recruitment of 
repressors that recognize and bind to 5-methylcytosines, called methyl-CpG-binding domain 
 
 
Transmethylation 
Transsulfuration 
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(MBD) proteins; or, by direct interference with the transcription-factor binding, thus preventing 
the interaction between the DNA-binding protein and their specific DNA sites (28). In mammals, 
there are five well characterized MBD proteins: methyl CpG binding protein 2 (MeCP2), MBD1, 
MBD2, MBD3 and MBD4; which are responsible for recruiting histone-modifier genes, resulting in 
transcriptionally inactive chromatin (29,30). 
The recent discovery of 5-hydroxymethylcytosine (5-hmC), which results from 
hydroxylation of 5-methylated cytosine (5-mC) by ten-eleven translocation (TET) proteins, has 
raised the possibility of an intermediate epigenetic state associated with changes in DNA 
methylation and transcriptional regulation during development, normal and disease states (31–
33). Although little is known about 5-hmC, several studies showed abundant levels of this 
modified base in pluripotent cells and neurons. Therefore, as 5-mC is considered the “fifth base” 
of DNA, 5-hmC has been pointed to be the “sixth base”(34,35). 
1.1.1.1. Methylation in the promoter region 
A gene promoter can be defined as a DNA sequence to which ribonucleic acid (RNA) 
polymerase binds to initiate gene transcription (36). According to CG density, promoters can be 
divided into 3 classes: low CG content promoters (LCPs), intermediate CG content promoters 
(ICPs) and high CG content promoters (HCPs) (18). Approximately 70% of all genes in the human 
genome have within them CGIs as well as about 50% of transcription start sites (TSS), which are 
considered the +1 position (18,36). The TSS represents the first nucleotide of first codon 
transcribed into RNA molecule, whose exact position is crucial for the identification of the 
regulatory regions that immediately flank it (37). 
In a normal state, HCPs tend to be unmethylated and related to housekeeping and specific 
well regulated developmental genes. In many hypomethylated HCPs, gene expression can be 
inactivated or non-productive, despite the normal action o RNA Polymerase II, and also show high 
levels of dimethylation of Lys4 of histone H3. In contrast, genes with LCPs are usually 
hypermethylated in somatic cells, and associated with tissue specific genes or with other genes 
required for their activation (18). 
However, when promoter methylation patterns are altered, chromatin conformation is 
altered, affecting directly gene expression, which can result into a disease development (Figure 2). 
Hypomethylation is intimately related with gene aberrant expression, whereas, hypermethylation 
has a silencing effect. These changes can occur either in promoters with CGIs or promoters not 
containing it, namely in CGI shores. The CGI shores can be defined as regions with lower CpG 
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density that lie in close proximity, but not within CGIs, and, therefore, its methylation have direct 
impact in gene expression, more precisely by silencing it (35,38). 
 
 
Figure 2 - Gene methylation in health and in disease. Alterations in promoter methylation patterns determine an open 
or closed chromatin conformation. Genes that do not have methylation in their promoters can become 
hypermethylated in pathological conditions (A), leading to silencing of genes naturally expressed. On the other hand, 
genes naturally silenced by methylation, can start to be pathologically expressed if methylation is lost (B). Furthermore, 
the same consequence can be observed in CpG island shores, whose methylation patterns alterations can lead to 
pathological transcriptional repression (C) or pathological gene expression (D). Reproduced from (30). 
1.1.2. Histone modification 
The nucleosome is composed by core histones, such as H2A, H2B, H3 and H4, which are 
grouped into two dimers of H2.A-H2.B and one H3-H4 tetramer; and a 147-bp segment of DNA 
wrapped in 1,65 turns around the histone octamer (39). Two consecutives nucleosomes are 
separated by approximately 50bp of free DNA. Histone H1 is not a part of the nucleosome, but it 
has an important function, by binding to linker DNA and ensuring the right location of 
nucleosomes. The core histones are predominantly globular, exhibiting unstructured N-terminal 
tails (40). All histones undergo post-transcriptional modification (PTM), mainly in their tails, such 
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as acetylation, methylation, phosphorylation, ubiquitination, sumoylation and ADP-ribosylation, 
which are important in transcriptional regulation, chromosome condensation, DNA repair, DNA 
replication and alternative splicing (41,42). Acetylation, ubiquitylation and sumoylation occur 
mainly in lysine (K) residues; whereas methylation affect arginine (R) and K residues; and 
phosphorylation occurs at serine (S) and threonine (T) residues (43). This is a reversible and 
dynamic process that involves the action of two antagonistic enzymatic complexes, responsible 
for adding or removing specific chemical group in specific sites (30). Usually, the nomenclature of 
PTM histones is the histone, followed by residue and its position and finally the PTM occurred, for 
example, acetylation of H3 in lysine residue in position 27 is represented by H3K27ac. 
The acetylation of lysine residues in the tail of histone is the most studied PTM and is 
associated with active transcriptional activity. In this PTM, the enzymes responsible for the 
attachment of an acetyl group to the histone tail are called histone acetyltransferases (HATs), 
while histone deacetylases (HDACs) are responsible for reverting it (40). HATs regulate gene 
transcription by interaction with transcription factors. HDACs have sequence specificity action 
since they depend on the recruitment by repressors, co-repressors and methyl-DNA binding 
proteins (44). 
According with the transcriptional levels, the human genome can be divided into 
euchromatin, with intense transcriptional activity; and heterochromatin, which is transcriptionally 
inactive. The first one shows high levels of acetylation, like in H3K27ac and H2BK5ac (promoter 
region), and usually H3 trimethylation in lysine residues of H3K4, H3K36 and H3K79; while 
heterochromatin exhibits low levels of acetylation and high level of methylation in H3K9, H3K27 
and H4K20 (45). 
1.1.3. Nucleosome positioning and miRNA 
The way like DNA is wrapped in nucleosomes interfere with the transcription process and, 
therefore, can affect all steps of gene expression regulation, as their/nucleosomes positions are 
able to prevent the activity of activator and transcription factors, affecting the elongation of RNA 
polymerase. Nucleosomes position at TSS is crucial for the initiation of transcription, once the 
presence and loss of nucleosome within the TSS is related to gene repression and activation, 
respectively (3). Despite controlling the accessibility of transcription factors to target DNA regions, 
disposition of nucleosomes directs meiotic recombination events and regulates methylation 
patterns, while chromatin remodeling is influenced by histone variants incorporated in DNA and 
DNA methylation (46,47). 
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There are 4 families of complexes, known as chromatin remodeling complexes that are 
responsible for all events regarding nucleosomes. All of these complexes rely on ATP hydrolysis, 
comprise an ATPase domain, and differ only in the composition of their unique subunits. The 
Switch/Sucrose Nonfermentable (SWI/SNF) family complexes have been proved to be regulators 
of gene expression and participate in alternative splicing [Reviewed in (48)]. The imitation switch 
(ISWI) family is associated with chromatin assembly and transcription repression, with only one 
exception complex, nucleosome remodeling factor (NURF) that participates in transcriptional 
activation. The third group is chromodomain helicase DNA-binding (CHD) family that is not only 
involved in the sliding and ejection of nucleosomes (gene expression), but can also have 
repressive activity, when the complexes have histone deacetylase activity and methyl-CpG-
binding domain proteins. The last family, designated as INO80, participates in a variety of cellular 
processes such as transcription activation, DNA repair and replication, telomere regulation and 
chromosome segregation. A member of this last family, SWR1 is capable of replace H2A-H2B 
dimers with H2A.Z-H2B dimers [Reviewed in (49,50)]. 
MicroRNAs (miRNAs) are also able to regulate chromatin remodeling through the 
interaction with complexes responsible for it, more precisely, mediating the specific subunits 
changes (51). Despite this action, miRNAs also control histone variant replacement. The miRNAs 
are RNA molecules, usually composed by approximately 22 nucleotides, whose function is to 
participate in gene expression regulation (52). There are two ways by which miRNAs can operate: 
they can bind to mRNA target with total complementarity and lead to its complete degradation; 
or bind to a less complementarity region, such as 3’ UTR regions, and suppress translation of the 
target gene [Reviewed in (53,54)]. Therefore, one miRNA can have multiple target regions and can 
interfere with regulation of multiple different genes (55,56). 
microRNAs are members of non-coding RNAs (ncRNAs) and result from the processing of 
a long primary transcript, with one or more precursor miRNAs; or short hairpin introns by direct 
intron splicing, although this last is only for a subset of miRNAs. These processes result in the 
formation of pre-miRNAS with a length usually between 70-100 nucleotides, which are routed 
towards the cytoplasm by the karyopherin exportin-5. In the cytoplasm, pre-miRNAs are 
processed by endonuclease RNase III Dicer and RNA helicase, resulting in a single strand mature 
miRNA that is later assembled to the RNA-induced silencing complex (RISC). Although miRNAs are 
an area with much to be discovered, it is known that the major responsible for the transcription of 
miRNAs is RNA polymerase II, in what concerns the tissue specific genes allowing their spatially 
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and temporally regulation. The housekeeping ncRNA genes expressed in all types of cells have 
their transcription through RNA polymerase III [Reviewed in (57)]. 
The miRNAs may contribute to DNA methylation since all enzymes responsible for DNA 
methylation DNMT1, 3a and 3b are predicted to be miRNAs targets (52). Furthermore, DNA 
methylation and histone modification can affect miRNAs expression (58). Also, miRNAs are 
possible to be regulated by specific promoters that can be contained within CpG island and, 
therefore, DNA methylation maybe one process that might regulate miRNAs expression (59). 
 
 
Epigenetic regulation of gene expression has a major importance in rapid cell adaptation 
to environmental conditions changes during life and across multiple generations. In brain, these 
mechanisms allow brain plasticity in response to experiences during lifetime. Although epigenetic 
mechanisms allow adaptive responses to positive and beneficial experiences, adverse 
environmental conditions can also induce neuronal responses that may culminate in pathological 
processes. Neuronal plasticity and susceptibility to neurological disease  are dependent on 
experience and environment conditions (60,61).  
 
 
1.2. ALZHEIMER DISEASE, THE MOST COMMON FORM OF DEMENTIA 
Alzheimer’s disease (AD) is the major cause of dementia in the elderly (62). The diagnosis 
of AD is most often based on the criteria from the National Institute of Neurologic and 
Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) which can result in three kinds of diagnosis: definitive, which has a clinical 
diagnosis with histologic confirmation; probable, characterized by typical clinical syndrome 
without histologic confirmation; and possible, when the patient presents atypical clinical features 
but no alternative diagnosis apparent without histologic confirmation (63,64). The classical clinical 
features of AD are an amnesic type of memory impairment, deterioration of language, and visuo-
spatial deficits (65). In late phases of the disease patients may exhibit motor and sensory 
abnormalities, gait disturbances and seizures (64). 
Alzheimers disease is a complex neurodegenerative disorder characterized by two forms 
of the disease: a familial form (early-onset incidence) that is rare and follows Mendelian 
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inheritance; and a sporadic or idiopathic form (late-onset incidence), which is the most common 
form of this dementia (66). Regarding the typical pathological hallmarks of the disease, there are 
no differences between sporadic and familial AD forms (67,68).  
1.2.1. Epidemiology 
According to several studies, approximately 4,6 million new cases are known every year 
and, at age of 60, North America and Western Europe exhibit the higher prevalence numbers for 
AD (69). For population with age above 65 years old, the prevalence of dementia, predominantly 
AD, increases exponentially almost 15-fold as well as the annual incident rate ( 
. The incidence rates of AD are difficult to determine accurately due to two factors: the 
determination of the exact onset age and the establishment of a study population without this 
disease (70,71). In Portugal, it is estimated that 153 000 persons suffer from dementia, in which 
AD is the cause of 90 000 cases (72). 
 
 
 
 
 
1.2.2. Histological and molecular insights 
Although the macroscopic alterations in the brain do not allow the diagnosis of AD 
patients, because they are not limited to AD patients, the histological examination of the post 
mortem brain tissue samples can determine a definitive diagnosis of AD (73). Histological analysis 
of AD brain tissue shows the presence of senile plaques (SPs), neurofibrillary tangles (NFTs) and 
extensive neuronal loss in specific brain regions (Figure 4) (65). 
Figure 3 - Annual incidence rate for AD. Adapted from (70). 
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Figure 4 - Histopahtological hallmakrs of AD. Histological samples of temporal cortex of an AD patient showing SPs 
(black arrows) and NFTs (red arrow) by modified Bielschowski stain (A) and aggregates of Aβ (component of senile 
plaques) stained with an antibody directed against the components of Aβ (B). Adapted from (73). 
The neuropathological features of AD brain encompass abundant SPs and NFTs, the later 
containing hyperphosphorylated tau; dramatic loss of synapses and neurons in the hippocampus 
and cerebral cortex; dystrophic neuritis astrogliosis; and microgial cell activation (68,74). All of 
these features have specific distributions, for example the SPs are found throughout the cortical 
mantle but NFTs are primarily found in limbic and association cortices(75,76). 
The main element of SPs is the amyloid-β (Aβ) peptide, which is a peptide with 38-43 
aminoacids originated from cleavage of the amyloid precursor protein (APP) (68,77). The exact 
role played by APP in a physiological manner is yet to be clarified, although it is known that APP 
participates in a variety of processes, such as cell growth, motility, neurite outgrowth, synapse 
formation (synaptic scaling and synaptic vesicle release), neural plasticity and cell survival (78). 
APP is the only protein of its family whose cleavage originates an amyloidogenic fragment. APP 
transcript can generated up to 8 isoforms through alternative splicing, including one isoform with 
695 amino acids, which is mainly expressed in the central nervous system (CNS)(79). 
The APP can be processed through a variety of pathways, some of which originate peptide 
Aβ (Figure 5) (78). At the cell surface, APP can be processed in an amyloidogenic or 
nonamyloidogenic pathway. The first pathway encompasses the cleavage of APP first by β-
secretase followed by γ-secretase, resulting in the production and release of the Aβ peptide, 
whose most common isoforms have 40 and 42 amino-acids. The Aβ suffers complex 
conformational changes, aggregating and originating soluble fragments and oligomers, with highly 
neurotoxic effects. As Aβ is continuously produced and accumulated, the soluble fragments and 
oligomers transit to large fibrils which are then deposited into SPs (68,78). Due to the higher 
degree of fibrilization and insolubility, Aβ42 is the most common isoform present in SPs (74). In 
A B 
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the nonamyloidogenic pathway α-secretase cleavage precludes Aβ formation, releasing instead a 
fragment followed by γ-secretase cleavage, called p3. The p3 fragment has low aggregation 
capacity and is not able to form oligomers. The γ-secretase is a multiprotein complex responsible 
for the sequencial intramembranous proteolysis of multiple transmembrane proteins, which is 
constituted by presenilin 1 (PSEN1) or presenilin 2 (PSEN2), nicastrin and two multipass 
transmembrane proteins (Aph-1 and Pen-2) [Reviewed in (80)]. Along with p3 and Aβ fragments, 
another fragment, called the APP intracellular domain (AICD), is also released. The AICD is 
responsible to facilitate the interaction of APP with various cytosolic proteins that regulate APP’s 
intracellular trafficking and/or signal transduction function; it has also been reported to possess 
transactivation activity and regulatory functions, being able to regulate transcription of multiple 
genes including APP, glycogen synthase kinase 3 (GSK-3β), β-site amyloid precursor protein 
cleaving enzyme 1 (BACE1); as well as, induction of apoptosis [Reviewed in (81)]. 
 
 
Figure 5 - APP processing pathways. The p3 fragment, originated via nonamyloidogenic processing, has poorer 
aggregation properties in comparison with Aβ that is responsible from SPs formation. Adapted from (78) 
The NFTs are essentially composed by the microtubule associated protein tau, which has a 
very important role in stabilizing structure of microtubules. In the NFTs, tau is abnormally 
hyperphosphorylated and aberrantly misfolded (74). Three stages can be defined according with 
NFTs formation and cellular distribution: first, pre-NFTs characterized by a diffuse, and sometimes 
punctuate, pattern present in normal neurons with normal morphology; secondly, fibrillar 
intraneuronal NFTs, that result from aggregation of tau protein into cytoplasmic filaments, 
Senile 
Plaques Aβ-42 
Aβ-40 
Aβ-38 
Nonamyloidogenic Amyloidogenic 
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observed in neurons with misplaced nucleus and distorted-appearing dendrites; and third, 
extraneuronal NFTs that consists of NFTs released into extracellular compartment due to the 
death of neurons with intraneuronal NFTs. The severity and duration of dementia have been 
correlated with the extent and distribution of NFTs. However the exact role of NFTs in AD is 
unclear, remaining two hypothesis: NFTs as a pathological mechanism and precursor of neuronal 
death in AD or as a neuroprotective mechanism in order to diminish neuronal damage (82,83). 
1.2.3. Genetic component and Risk Factors for AD 
The early onset of AD accounts for about 5% of all diagnosis of AD, affecting people below 
65 years, with a familial history and an autosomal dominant transmission pattern (66). This form 
is associated with mutations in the genes of APP, PSEN1 and PSEN2 (84–86). However not all 
early-onset AD patients have mutations in this 3 genes, indicating that another mechanism may 
be also responsible for it (87).  
Until now, 33 pathogenic mutations in APP gene have been described 
(http://www.molgen.vib-ua.be/ADMutations/default.cfm?MT=0&ML=1&Page=AD). These 
mutations can either be a duplication of the gene segment or a point mutation in the promoter 
region, resulting in the increase of wild-type protein or mRNA levels, respectively. The PSEN1 is a 
conserved polytopic membrane protein that mediates the γ-secretase cleavage of APP, and 
mutations in this gene result in increased Aβ production (88). Since discovery of this gene, the 
number of described mutations is increasing, being more than 180 so far. Mutations in PSEN2 
have been also found but, despite its significant homology with PSEN1, the result of its mutations 
is less severe and the age of onset is usually higher. Furthermore, the disease progression is 
slower than what is observed in APP and PSEN1 mutations. These 3 genes belong to the same 
biochemical pathways that results in the alterations of Aβ production, increasing the abundance 
of Aβ-42 species and, consequently, SPs. However, several familial early-onset AD are not related 
to mutations in any of the genes above mentioned, underlying the role of other candidate 
proteins involved in APP processing or other mechanism yet to be discovered (66). 
On the other hand, late onset AD encompasses 95% of all AD cases and don’t exhibit any 
familial disease history and, therefore, is very complex. The only high risk factor proved this far to 
be associated with AD is apoliprotein E (ApoE) (89). There are three major alleles of ApoE locus 
that result from combinations of two amino acids changes in 112 and 158 residues of protein 
(Figure 6). The ApoE allele Ɛ2 encodes Cys at 112 and 158 residues; the allele Ɛ3 originates Cys at 
residue 112 and at 158 an arginine; and allele Ɛ4 which encodes arginine in both residues. Large 
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studies have proved the higher risk to develop AD in patients with Ɛ4 presence (90). In contrast, 
studies pointed to a protective action of Ɛ2 (87). However, it is important to highlight that ApoE 
Ɛ4 does not reflect per se the development of AD, but it increases the predisposition to it.  
 
Figure 6 - ApoE alleles. Nucleotide alterations in exon 4 of ApoE gene are responsible for the three 
ApoE alleles, determining the encoded ammino acid in 112 and 158 residues. The ApoE allele Ɛ4 
carriers have increased risk of developing AD. Reproduced from (87). 
1.2.4. Diagnosis of dementia 
Since many dementing disorders exhibit higher overlap degree of symptomatology, 
pathological and molecular pathways, the differential diagnosis among pathologies is sometimes 
difficult. The differential diagnosis is done by clinical evaluation that includes and combine 
information from cognitive and behavior assessment, neuroimaging findings, genetic tests and 
levels of certain proteins in cerebral spinal fluid (CSF). 
The clinical diagnose of dementia is mainly based on medical history and cognitive 
evaluation for exclusion of other dementias and to target to more specific examinations. At early 
stages of dementia, specific patterns of cognitive and behavioural dysfunctions reflect disruption 
of specific brain regions and structures. Among the most commonly used cognitive screening tool 
is Mini-Mental State Examination (MMSE) (91). The MMSE is a 30-point test of cognitive function 
that contains tests of attention working memory, episodic memory (orientation and recall), 
language comprehension, visual-spatial functions, naming and copying. The MMSE should be 
complemented with other neuropsychological tests such as DemTect or clock drawing test, as 
several AD and mild cognitive impairment patients exhibit normal MMSE scores (92,93). Non-
cognitive symptoms of dementia, such as apathy, psychosis, affective and hyperactive behaviours, 
DNA methylation as a potential biomarker for Alzheimer Disease 
 
16 
 
should also be assessed, using for example geriatric depression scale (94); not only because they 
are supportive features in the diagnosis of non-AD dementias like Dementia with Lewy Bodies 
(DLB), Parkinson’s Disease with Dementia and Frontotemporal Dementia (FTD); but also due to its 
association with declining cognitive and functional ability and decreased quality of life. For 
example, the Middelheim Frontality Score (MFS) allows the measurement of frontal features 
distinguishing FTD from AD patients with sensitivity and specificity of almost 90% (95). As 
impairment of daily living activities are key features of dementia, they must be evaluated using 
different scales, such as AD Cooperative Study Activities of Daily Living Scale, Functional Activities 
Questionnaire (FAQ) and Progressive Deterioration Scale (PDS). Most of these scales include 
measurement of basic activities involving self-maintenance skill, like eating, dressing, bathing; and 
instrumental activities, which require the use of complex higher order skills as devices, managing 
finances and shopping [Reviewed in (93)]. 
The neuroimaging tools like computed tomography and magnetic resonance imaging are 
used to exclude secondary causes for dementia, such as tumor, inflammatory disease, including 
abscess or normal-pressure hydrocephalus; or to support and complement clinical features 
through the evidence of brain regions atrophy [Reviewed in (96)]. Electroencephalography (EEG) 
is important to provide evidence for Creutzfeldt-Jakob Disease but can also be used to support 
differential diagnosis of neurodegenerative dementias like AD, DLB, Vascular Dementia (VaD). EEG 
diffuse abnormalities points to AD but when diffuse and focal changes are both presence DLB, 
VaD or AD may be the cause (91). 
Further, new neurochemical evaluation of CSF can presently assist clinical diagnosis of 
dementia and contribute to a more accurate diagnosis. This neurochemical diagnosis can be used 
in differential diagnosis of dementia in particular to distinguish AD from other type of dementia 
(such as VaD, FTD, DLB). The neurochemical analysis are important in directing towards the right 
diagnosis, but all results must be interpreted with caution and always depending on clinical data 
and other diagnostic techniques, such as neuroimaging and neuropsychological testing (97). 
1.3. EPIGENETIC AND ALZHEIMER’S DISEASE 
The loss of phenotypic plasticity over time is a definition for aging, which is characterized, 
at the cellular level, by oxidative stress, disturbed calcium homeostasis, chromosomal instability, 
impaired DNA repair and accumulation of nuclear and mitochondrial DNA damage (43). All these 
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features can lead to neuronal aging, neurodegeneration, and cell death in the central nervous 
system (98).  
Neurodegenerative diseases are complex disorders that are characterized by the interplay 
of many genes in their pathology. These complex disorders are characterized by non-Mendelian 
characteristics, with more percentage of sporadic etiology cases than familiar ones, incomplete 
concordance rates for monozygotic twins differential susceptibility between males and females, 
monoalelic expression of susceptibility genes and parent-of-origin effects (16). Epigenetic 
alterations can explain all these features and aberrant DNA methylation has been shown to be 
implicated in the pathophysiology of some neurodegenerative diseases [Reviewed in (99)].  
Aging is associated with multiple epigenetic alterations and, since it is the major risk 
factor for AD, may be the mechanism that establishes the connection between 
environmental/dietary factors and AD development and progression. The normal cell aging 
process is also associated with a DNA methylation drift with generally global decrease in genomic 
5mC in the brain , as well as hypomethylation in all genomic compartments, such as promoter, 
exonic, intronic, and intergenic regions (100,101). 
1.3.1. DNA methylation and AD 
In the pathogenesis of AD both hypermethylation and hypomethylation can occur 
simultaneously in different genes contributing to AD progression (98). AD brains show elevated 
levels of S-adenosylhomocysteine, a potencial inhibitor of methyltransferases that is inversely 
correlated with patient cognition (102). The promoter CpGs from AD-associated genes, such as 
APP, PSEN1 and BACE1 have been reported to be hypomethylated which lead to their abnormal 
upregulation and the excessive accumulation of Aβ peptide. Promoters of other genes like ApoE 
and methylenetetrahydrofolate reductase of AD brains cortex showed hypermethylation 
patterns(101,103). 
The frequent methylation of some cytosines in APP promoter region in patients with age 
below 70 years, and the opposite (demethylation) in patients with age above 70 years, supports 
that model, since the demethylation of APP promoter region can result in an increased APP 
producing and processing, contributing to AD progression (104). A recent study points to the 
importance DNMT3a2 as a potential drug target for enhancing or restoring cognitive function due 
to its interplay in long-term memories and the fact that reduced levels of DNMT3a2 in 
hippocampus of aged mice models are correlated with cognitive decline through aging (105). 
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The methylation analysis of PSEN1, ApoE, Metilenotetrahidrofolato redutase (MTHFR) and 
DNMT1 genes, the last two involved in methylation homeostasis, pointed to an interindividual 
epigenetic variability both in post-mortem brain and lymphocytes of AD patients, which may 
contribute to predisposition to late-onset AD (101). Another study of promoter methylation in 
peripheral blood genomic DNA, revealed hypermethylation of human telomerase reverse 
transcriptase (HTERT) in AD patients when compared with age matched controls. This gene 
encodes mRNA that is a component of telomerase and is activated by DNA methylation, in 
contrast with the normal silencing effect of this epigenetic modification (106). 
From a genome-wide perspective, some studies reported decreased DNA methylation in 
AD, compared with age matched healthy control, in cortical neurons and glia, through 
immunoreactivity of several markers of DNA methylation. However, no changes in methylation 
were observed in cerebellum, an area that is not affected in AD patients (107). The same results 
were also obtained in a study of monozygotic twins discordant for AD and APP-overexpressing 
transgenic mice (108,109). 
1.3.1.1. DNA methylation as a potential biomarker candidate 
Biomarkers can be defined as biological molecules in body fluids or tissues that are 
quantitatively measured and evaluated as indicators of normal biological processes, pathogenesis, 
or pharmacologic response to therapeutic intervention (110). DNA methylation can easily be 
detected in a variety of samples, such as tissue and body fluids like peripheral blood and plasma, 
even in small amounts (111). Aberrant DNA methylation is a well-recognized hallmark of many 
complex diseases such as heart disease, diabetes, neurological disorders and cancer (35). Global 
methylation in peripheral blood leukocytes significantly differed between healthy controls and 
patients with pancreatic cancer, breast cancer, bladder cancer and colorectal adenoma (112–
115). 
As neurodegenerative disorders have many non-mendelian features, DNA methylation 
and other epigenetic mechanisms may contribute to the disease pathology and have been 
extensively studied in order to explain their etiology. Global hypomethylation and hyper and 
hypomethylation of disease-related genes was detected in postmortem brain tissue of AD 
patients (104,107,116). Furthermore alterations in DNA methylation levels of several 
neurodegenerative disorders in peripheral blood cells had also been identified (Table 1). 
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Table 1 - DNA methylation alterations in peripheral blood cells in neurodegenerative disorders. 
Neurodegenerative 
disorders 
Studied 
Region/gene 
DNA methylation 
alteration 
References 
Alzheimer Disease 
ApoE; MTHFR; 
HTERT 
Hypermethylation (101,106) 
Parkinson Disease 
Subtelomeric regions 
of short telomeres 
Hypomethylated 
subtelomeres 
(117) 
Multiple Sclerosis 
CDKN2B Hypermethylation 
(118) 
MYF3 and RB1 Hypomethylation 
 
DNA methylation has still several limitations that need to be overcome. The clinical use of 
DNA methylation in peripheral blood leukocytes and whole blood is uncertain as they might not 
reflect the methylation of target tissues. This limitation is especially important in neurological 
disorders due to the fact that it is impossible to evaluate the methylation levels in non-
postmortem brain samples. Furthermore, DNA methylation analysis techniques don’t allow the 
distinction between 5-mC and 5-hmC, 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC); and 
are unable to differentiate heterogeneous methylation patterns in different cells present within 
samples (119). 
1.3.2. Epigenetic as a potential therapeutic target 
Since the discovery of epigenetics, many drugs proved to be capable of reverting 
abnormal epigenetic changes in particular in cancer and mental disorders. The drugs used can be 
divided into two classes: DNA methylation inhibitors and HDAC inhibitors (HDACis) (120). 
Histone post-translational acetylation is intimately related to gene expression and, 
therefore, due to histone deacylation, HDAC action leads to suppression of critical genes in cancer 
[Reviewed in (121,122)]. Owing to this fact, HDACis were also considered potential targets for 
mental pathologies and several studies have been carried out with this purpose (123). 
Chromatin acetylation plays a role in memory formation (124) and HDACis proved to 
improve memory and induce dendritic formation, in transgenic mouse model of 
neurodegeneration (125). These results points to a potential use of HDACis in treating 
neurodegeneration and memory loss; however, few data regarding the effects of HDACis in brain 
is available and, despite that, specific gene targets and function in neurodegenerative disorders 
are still to be revealed (24). 
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The histone methyltransferase (HMTase) and histone demethylases inhibitors are new 
groups of drugs that are being developed that may be of therapeutic value. HMTase inhibitors 
could be used to activate silenced genes but their effects in humans are still to be determined. 
Alternatively, methylation in different histones and different residues can lead either to gene 
expression or silencing, for example, H3K9Me2 is related to gene silencing and H3K4Me2 with 
gene activators; being the state of histone methylation a balance between methylation and 
demethylation (24,126). 
Potentially, DNA methylation can also be a therapeutic target that could allow the change 
of pathological gene expression. However, a few issues needs to be taken into account: it is 
necessary to understand the methylation patterns in the disease, the complexity of the DNA 
methylation machinery and the interactions of this machinery with other important processes of 
the cell (24). 
Recently Food and Drug Administration approved DNA methylation inhibitors (5-
azacytidine (5-aza) and its analogue 5-deoxycytidine), whose application thus far is restricted to 
myelodysplastic syndromes (127,128). Besides these two compounds, another DNA methylation 
inhibitor (Zebularine) has the same mode of action but is chemically more stable and orally 
bioavailable (129). The mechanism of action of these compounds is based on the inability of 
DNMT to break the covalent bond to 5’-aza-cytosine. After entering the cell these compounds are 
phosphorilated to triphosphate nucleotide and incorporate into DNA during DNA replication, 
resulting in a new strand without methylation, but the template strand with the same 
methylation pattern [Reviewed in (130)]. Nevertheless, since brain has little mitotic activity the 
use of these compounds to prevent methylation effects is limited. Furthermore, a study, using 
these DNA methylation inhibitors, show that long term potential was blocked and was not able to 
prove with confidence any interaction with DNMT1 (131).  
A study using 5-aza in peripheral leucocytes revealed that AD patients lost DNA 
methylation levels compared with normal and age matched controls, pointing to a deregulation of 
this process in AD patients (132). Another study, using in vitro models, reported that HDACis 
largely increase H3 and H4 hyperacetylation and the up-regulation of cytotoxic genes, pointing to 
a histone acetyltransferases inhibitor therapeutic potential in AD (133). This evidence is supported 
by the decreased risk of developing AD in people consuming large curcumin, a HAT inhibitor that 
interfere with SPs (134–136). 
Therefore, if we think a therapeutic perspective for neuropathologies, there is a need to 
discover compounds that can affect DNA methylation but independently of the need of DNA 
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replication, without cell toxicity and able to inhibit directly DNA methyltransferases action. 
Several compounds have been proposed but they are still in study (137,138) [Reviewed in (130)]. 
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DNA methylation is the major studied epigenetic mechanism and consists in the addition 
of a methyl group to 5’ carbon position of the cytosine ring. In mammals, DNA methylation occurs 
in CpG dinucleotide that can belong to CpG Islands or CpG Island shores. Methylation of promoter 
gene regions are directly correlated with gene silencing, which can allow the development of 
certain diseases as important genes are not expressed due to its promoter methylation. Likewise 
hypometylation profiles can also be translated into gene expression alterations. Aging is the major 
risk factor for AD, and also the process underlying many of the epigenetic alterations. 
Detection of global or gene-specific methylation changes can constitute important 
biomarkers in neurodegenerative disorders, and has also been focus of attention in AD. 
Furthermore, its evaluation using DNA extracted from body fluids, such as whole blood, constitute 
a non-invasive method, and, therefore, can allow easier and routine biomarker assessment. 
The main goal of this study was to evaluate global or gene-specific methylation changes 
between possible AD patients and age- and sex-matched controls, therefore the specific aims of 
this thesis were to: 
(1) Quantify the DNA global methylation levels in possible Alzheimer Disease (AD) 
patients and compare them with age- and sex-matched healthy controls in a 
Portuguese pilot study; 
(2) Evaluate gene-specific methylation profiles of AD-related genes, namely APP and 
ApoE, by Combined Bisulfite Restriction Analysis (COBRA); 
(3) Set up the Methylation Sensitive – High Resolution Melting (MS-HRM) conditions to 
evaluate AD-related gene sequences through melt curve analysis; 
(4) Evaluate methylation profiles of the AD-related genes by Bisulfite Direct 
Sequencing. 
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3.1. SAMPLE CHARACTERIZATION 
Inclusion criteria for the study group were: age ranging between 50-90 years, resident in 
the Aveiro region, with complaints including objective memory impairment or other cognitive 
symptoms. The exclusion criteria were if individuals undergoing chemotherapy or radiotherapy, 
psychiatric illness such as bipolar disorder and schizophrenia, and the use of illicit drugs.  
The cognitive evaluation of individuals was carried out at several Centers for Primary 
Health Care in the Aveiro region. The project was approved by the ethics committee of the 
Regional Health Center - Coimbra, protocol number 012 804 of April 4, 2012. 
The Clinical Dementia Rating scale (CDR) (139,140) the Mini-Mental State Examination 
(MMSE) (141), and the Geriatric Depression Scale (GDS) (142,143) were the cognitive testes 
applied to the study group. The CDR scale: 0 indicates normal function; 0.5 indicates a transition 
level (termed questionable dementia); 1.0 indicates signiﬁcant cognitive function loss (almost 
always a clear correlation with dementia); 2.0 indicates loss of moderate cognitive function; and 
3.0 indicates severe loss. For this study cognitive dysfunction was considered when CDR ≥ 0.5. The 
MMSE test allows patient stratification according to the education level: cutoff of 22 for 0-2 years 
schoolarship; 24 for 3-6 years; and 27 for more than 7 years. Additionally, clinical routine 
questions were included to address other possible neurological pathologies. All depressed 
individuals were excluded using the GDS scale. This Scale (142,143) consists of 15 questions, in 
order to survey suggestive symptoms suggestive of depression, in which individuals with 0-5 
positive questions were considered normal. 
According to the cognitive evaluation, individuals were subdivided in 2 groups: the age- 
and sex-matched control group (negative for the 3 tests) and the possible AD group (positive for 
CDR and MMSE scales, negative for GDS). 
This study included, 9 possible AD patients and 7 aged- and sex-matched controls 
(matched as much as possible) from which 2 age- and sex-matched controls and 2 possible AD 
patients are male. Along with these samples, 1 internal positive control (IPC), which had been 
diagnosed as AD based on the neurochemical assay of the biomarker triplet (Aβ, total Tau and 
phospho-tau), was also used and the methylation levels evaluated as for the other samples. The 
mean age for controls is 72 years old and for possible AD patients is 73 years old. 
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3.2. GENOMIC DNA EXTRACTION 
Genomic DNA from samples was extracted using QIAamp DNA Blood Mini Kit (QIAGEN), 
using 200μl of whole blood from each sample (Figure 7), according to manufactures instructions. 
The whole blood was added to 20μl of QIAGEN Protease to degrade proteins. In order to 
guarantee genomic DNA without RNA contamination, 4μl of RNase A (100 mg/ml) was added 
afterwards. To ensure efficient cell lysis, 200μl of Buffer AL was added to the microcentrifuge tube 
and mixed, by pulse-vortexing, followed by incubation at 56°C for 15 min. 
After centrifugation, 200μl of ethanol (96-100%) were added. The total mixture was 
applied to QIAamp Mini spin column and centrifuged at 8000rpm for 1 min, allowing the genomic 
DNA to be retained in silica membrane. 
Two wash steps were then performed using Buffer AW1 and Buffer AW2 wash solutions. 
In the first wash step, 500μl of Buffer AW1 were added to spin columns and centrifuged at 8000 
rpm for 1 min. Next, 500μl of Buffer AW2 were also added to spin columns, followed by 
centrifugation at 14000rpm during 3 min. In order to remove all residues of ethanol and other 
solutions that may interfere with downstream analysis, an additional centrifugation was 
performed at 14000 rpm during 1 min.  
Finally, the genomic DNA was eluted with Buffer AE, in a total elution volume of 80μl. The 
quantification and purity of genomic DNA was carried out using NanoDrop Spectrophotometer 
ND-1000 (Thermo Scientific) and the integrity was visualized by 1% agarose gel electrophoresis. 
 
Figure 7 – General steps for pure genomic DNA extraction from whole blood. Blue circular arrow – centrifugation at 
8000 rpm; Red circular arrow – centrifugation at 14000rpm. Adapted from QIAamp DNA Blood Mini Kit manual. 
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3.3. GLOBAL METHYLATION ANALYSIS 
For global methylation analysis, Abnova Methylated Quantification Kit (colorimetric) was 
used which is an enzyme-linked immuno sorbent assay (ELISA) format (Figure 8). For 
quantification through standard curve, DNA methylated (ME4) control provided in the kit was 
used to generate five different standard DNA methylation concentrations by dilution in TE 1x 
buffer as following: 0; 0,5; 1; 2; 5; and 10 ng/μl. Unmethylated (ME3) control was used as a 
negative control. 
 
Figure 8 - Schematic representation of the Methylated DNA Quantification by ELISA. 
Initially DNA is bound to plate well and then capture using antibodies that recognize 
methylated cytosines. In order to quantify methylated DNA, substrate is added and 
optical density measured. Extracted from Abnova Methylated Quantification Kit. 
 
After the standard curve preparation, 80μl of Binding Solution (ME2) was added to each 
well, followed by samples and standards. For each control 1μl was used. For samples the amount 
of genomic DNA input was 200ng, previously determined based on NanoDrop Spectrophotometer 
ND-1000 (Thermo Scientific) quantification, ranging in a volume between 1μl and 8μl. All samples 
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and standards were run in duplicates. The plate was incubated at 37°C during 90 min, followed by 
three washes with ME1 1x Wash Buffer. 
Afterwards, the capture of methylated DNA was performed in three steps. First, 50μl of 
capture antibody (ME5) was introduced in each well and incubated at room temperature for 1h, 
to enable the recognition of methylated DNA. Secondly, the samples and controls were incubated 
with 50μl of detection antibody (ME6) at room temperature during 30 min. The last step was 
incubation at room temperature for another 30 min, with 50μl of enhancer solution (ME7) to 
increase the signal’s assay. Between all three steps, the wells were washed four times with ME1 
1x Wash Buffer. 
Finally, the signal was generated by adding the developer solution (ME8) and the 
enzymatic reaction was stopped (ME9) as soon as the most concentrated standard exhibit blue. 
Absorbance was measure at 450nm using TECAN infinite M200. The amount and percentages of 
methylated DNA were calculated according to manufacturer instructions, as following:. 
 
Figure 9 - Calculation of DNA methylation (5-mC) percentages. In 
order to determine the amount of methylated DNA, the optical 
density (OD) of negative control (ME3) is subtracted to OD of 
samples and divided by standard curve slope. However, as the 
methylated DNA control only has 50% of methylated cytosines, it 
was necessary to normalize samples dividing by 2. Then, the 
amount of methylated DNA is divided through the amount of DNA 
input followed by the multiplication by 100 to reach DNA 
methylation percentages. Extracted from Abnova Methylated 
Quantification Kit. 
3.4. BISULFITE DNA MODIFICATION 
Bisulfite conversion is a wide method to evaluate DNA methylation. Chemically, sodium 
bisulfite cytosine desamination is completed through three reactions (Figure 10). The first is 
sulphonation, which consists in the addition of bisulfite to the 5-6 double bond of cytosine, 
followed by hydrolytic deamination resulting in uracil-bisulfite derivate. The final step is alkali 
desulphonation that consists in the removal of sulphonate group by alkali treatment, originating 
uracil nucleotide. As methylated cytosine has a methyl group in position 5, they are protected 
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against bisulfite mediated deamination. In order to these reactions to occur, the DNA must be 
single stranded and, therefore, a correct denaturation step is crucial. After PCR, methylated 
cytosines remain intact and non-methylated cytosines appear in DNA fragment as timines (144). 
 
Figure 10 - Bisulfite conversion reactions. The three steps, sulphonation (1), hydrolic deamination 
(2),alkali desulphonation (3) lead to non-methylated cytosine desaminations and,subsequent, 
convertion into uracil. Extracted from (145) 
The bisulfite conversion was carried out using EZ DNA Methylation-Gold Kit (Zymo 
Research). For all samples 1μg of genomic DNA, calculated based on quantification of NanoDrop, 
was modified according with manufacture indications. A maximum of 40μl of DNA volume was 
used, and samples normalized for the volume using nuclease free water. The CT Modification 
Reagent was then added (110μl) and samples were submitted to the conditions present in Table 2 
using MyCyclerTM Thermal Cycler (BioRad). 
Table 2 - Bisulfite conversion conditions. 
Step Temperature (°C) Duration 
1 98 10 min 
2 64 2.5 hours 
3 4 hold 
Once bisulfite conversion finished the bisulfite modified DNA (bDNA) was bound to spin 
columns by mixing samples with 600μl of M-Binding Buffer, followed by centrifugation at 12000xg 
for 30 sec. Before the desulphonation step, the bDNA was washed using M-Wash Buffer and 
centrifuged for 30 sec. In order to remove residues of bisulfite conversion reagent, 200μl of M-
Desulphonation Buffer was added to the columns and incubated for 20 min at room temperature. 
Next, the columns were centrifuged and two wash steps performed as mentioned above to 
ensure the complete removal of PCR inhibitors, like ethanol or even any remaining of the 
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desulphonation solution. Finally, the bDNA was eluted using nuclease free water. To increase the 
elution efficiency, before centrifugation at 12000 xg for 30 sec, the columns were incubated for 5 
minutes at room temperature. After bisulfite modification, the bDNA is a single strand molecule 
with both DNA and RNA features and thereby it is not accurately quantified by spectrometry. The 
bDNA was stored at -80°C. 
3.5. SELECTION OF METHYLATED GENE REGION 
The sequence from APP and ApoE was extracted from UCSC Genome Bioinformatics, with 
4000 bases upstream gene region, and blasted in the NCBI to verify its identity. Information 
regarding the APP and ApoE sequences used is present in Table 3. For each gene, the translation 
start codon was assessed through NCBI search and the transcription start site (TSS) annotated 
base on research articles (146,147).  
Table 3 – Information about genes sequences according to UCSC Genome Bioinformatics. 
Gene Reference Sequence Chromosome Chromosome position 
ApoE NM_000041 19 45406039-45412650 
APP 
NM_001204301 21 27252861-27546138 
The gene sequences were introduced in CpG Island Searcher (http://cpgislands.usc.edu/), 
in order to find CGIs. The CGIs were also confirmed during primer design, using the Methyl Primer 
Express v1.0 (Applied Biosystems) software.  
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Figure 11 - CpG islands present in APP promoter region sequence. The selected and amplified region is localized 
between primers. The major transcription start site (TSS) was annotated based on Salbaum, 1988 (146). 
 
Figure 12 – The ApoE promoter sequence exhibit only one CpG Island upsteam transcriptional start site (TSS). The 
selected and amplified region is localized between primers. The TSS was annotated based on Paik, 1985 (147).  
3.6. PRIMER DESIGN 
The selected regions for APP and ApoE genes were selected according to TSS region and 
included the positions between -256 and +178 for APP and between the -120 and +283 for the 
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ApoE gene. The APP and ApoE selected sequences were introduced in Methyl Primer Express 
V1.0, a primer design software. This software is specific in designing primers for methylation 
analysis using bisulfite conversion, as it converts automatically genomic sequence and show the 
best primer pairs for bisulfite modified DNA. For APP 3 sets of primers were designed; one for 
Combine Bisulfite Restriction Analysis (COBRA) and two for Methylation Sensitive - High 
Resolution Melting (MS-HRM), and for ApoE only one set of primers were designed. In MS-HRM, 
APP promoter region was set to two fragments of approximately 250bp in order to provide better 
analysis due to high CpG density. The primers used in each approach will be identified in the 
corresponding sections. 
The sets of primers designed were tested for self-complementary and hetero dimerization 
using AutoDimer V1. All sets of primers exhibit interactions below score number 4, despite the 
acceptable score for multiplex PCR being 7. The primer sets were also tested in other software 
such as Thermo Scientific Multiple Primer Analyzer (available in 
http://www.thermoscientificbio.com/webtools/multipleprimer/), exhibiting low levels of 
interactions. Temperature melting of primers was also estimated using IDT OligoAnalyzer 3.1 
(available in http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/). 
3.7. COMBINE BISULFITE RESTRICTION ANALYSIS  
The COBRA consists in amplification of a bisulfite modified genomic sequence using 
specific primers, followed by restriction analysis with enzymes that recognize methylation sites. 
After bisulfite treatment, only the non-methylated cytosines convert to uracil and, therefore, the 
recognition site for restriction enzymes of methylated cytosines remain the same. After PCR 
reaction, enzymatic restriction digestion products were run in an agarose gel to chase for the 
methylation pattern in each sample. 
3.7.1. Amplification of APP and ApoE sequences by PCR 
For this method the set of primers were designed as described in section 3.6. Table 4 
shows the primers used for APP and ApoE Genes. 
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Table 4 - Sets of primers used for ApoE and APP amplification for COBRA. 
Gene Primer sequence 
Annealing 
Temperature 
PCR product 
length 
ApoE 
Fw: 5' GGGTAGGGGGAGAATAGTTTAT 3' 
59°C 403bp 
Rv: 5' CTTACATCCCAATCCAACTACT 3' 
APP Fw: 5' TGGTTTTAGATTTTTTTTTTTATTGT 3' 
56°C 434bp 
Rv: 5' CCAACAAAAACAATACCAAACC 3' 
 
The PCR reactions were done in a final volume of 25μl as described in Table 5. 
Table 5 – PCR amplification reaction composition. 
Components Volume/reaction (μl) 
bDNA (≈20ng/μL) 5 
Master Mix 12.5 
Primer Fw (5μM) 1.5 
Primer Rv (5μM) 1.5 
Nuclease free water 4.5 
Total 25 
The PCR program, described in Table 6 and Table 7, was performed in MyCyclerTM Thermal 
Cycler (BioRad). 
Table 6 - PCR cycling conditions for APP gene amplification using Maxima HotStart. 
Number of cycles Step Temperature (°C) Duration 
1 Initial denaturation 95 10 min 
45 
Denaturation 95 30 sec 
Annealing 56 30 sec 
Extension 72 1 min 
1 Final extension 72 7 min 
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Table 7 - PCR cycling conditions for ApoE gene amplification using Kappa Uracil+. 
Number of cycles Step Temperature (°C) Duration 
1 Initial denaturation 95 5 min 
40 
Denaturation 98 20 sec 
Annealing 59 15 sec 
Extension 72 1 min 
1 Final extension 72 1 min 
 
3.7.1.1. Agarose gel electrophoresis 
Agarose gel electrophoresis is the method of choice for separating DNA fragments from 
different sizes. The phosphate groups charge negatively the DNA molecule allowing its migration 
to the positive terminal, when subjected to an electrical field. Since DNA has uniform mass/charge 
ratio, fragments from different sizes can be separated using the appropriate agarose percentage 
gel. The larger DNA fragments have less migration rate than small size DNA fragments. 
Furthermore, the migration rate also depends on the agarose concentration and type, the running 
buffer, the DNA conformation and the voltage applied (148). 
To confirm the presence of the expected DNA fragment, PCR products were visualized 
using 2% agarose gels prepared in 1x TAE Buffer. After boiling, the gel was cooled down to 60°C 
and then GreenSafe (NZYTech) was added to a final concentration of 0.025μl/ml and the solution 
poured into the gel tray to allow proper polymerization. Samples were prepared by adding 
glycerol in the ratio 1:6, to increase sample density. The DNA ladder 1kb plus (Invitrogen) was 
used. The gel was run at 90V for about 40 minutes. Finally, the gels were visualized under UV light 
in Gel Doc XR System (Bio-Rad). 
3.7.2. Restriction Enzyme Selection and Digestion 
The selection of the restriction enzyme was carried out using a simulator present in the In 
silico simulation of molecular biology experiments site (http://insilico.ehu.es/). After introducing 
the methylated sequence, the online tool generates an unmethylated sequence and tests all 
commercial available enzymes. The enzyme was chosen based on the cleavage sites in the 
methylated sequence, and consequently on the fragment pattern complexity obtained. 
The enzymes chosen were HhaI (recognition site: GCG’C) (Thermo Scientific) and SsiI 
(recognition site: G’CGG) (Thermo Scientific) to analyze APP (Figure 13) and ApoE (Figure 14), 
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respectively. The HhaI has seven potential cut sites in APP sequence, originating a maximum of 
eight fragments. On the other hand, SsiI has three potential cleavage points given rise to a 
maximum of four fragments, if all CpG exhibit methylation. 
 
Figure 13 – Restriction recognition sites of HhaI in amplified APP sequence (A) and 
fragments originated from methylated DNA digestion (B). 
 
Figure 14 – Restriction recognition sites of SsiI in amplified ApoE sequence (A) and 
fragments originated from methylated DNA digestion (B). 
The enzymatic digestion was performed at 37°C overnight (≈16 hours), as described in 
Table 8. 
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Table 8 - Enzymatic restriction mixture components. 
Components 
APP ApoE 
Volume/reaction (μl) Volume/reaction (μl) 
PCR product 17 17 
HhaI (10U/μl) 1 - 
SsiI (10U/μl) - 1 
Buffer Tango 2.5 - 
Buffer O - 2.5 
Nuclease free water 4.5 4.5 
Total 25 25 
The resulting restriction fragments were run analyzed in 3% agarose gel as described in 
section 3.7.1.1, using instead of TAE 1x, SGTB buffer 1x as it allows better results in separation of 
small DNA size fragments that may arise from enzymatic digestion (149). Gel was run at 200V for 
approximately 25min and visualized under UV light in Gel Doc XR System (Bio-Rad). 
Methylated and unmethylated DNA controls were used and treated exactly as the 
samples. The DNA of both controls came from HCT116 DKO cell which has genetic knockouts for 
DNA methyltransferases DNMT1 and DNMT3b. The DNA extracted from these cells has less than 
5% methylation and serves as unmethylated control. For the methylated control, the DNA was 
subjected to enzymatic methylation using M. SssI methyltransferase. Validation of unmethylated 
and methylated DNA controls were carried out by the manufacture by amplifying a specific region 
of the gene BRCA1 with methylated and unmethylated specific primers. 
3.8. METHYLATION-SENSITIVE HIGH RESOLUTION MELTING (MS-HRM) 
The MS-HRM is a recent technique that allows the DNA methylation quantification in a 
gene sequence by comparison with methylated and unmethylated standards, using real-time PCR 
technology. The initial step consists in the amplification of the sequence using primers that 
amplify regions regardless their methylation state. During the amplification, DNA binding dye 
intercalate with double strand DNA emitting fluorescence. After the amplification step, PCR 
products are gradually denatured by increasing the temperature in small increments, resulting in 
a characteristic melting profile. As the DNA denatures, the dyes are released and fluorescence is 
lost. According to high amount of C/G or A/T content of the DNA, it can denature at higher or 
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lower temperatures, respectively. The bDNA molecules differ only in cytosine content, with higher 
cytosine content having higher melting temperatures and high methylation percentages. Through 
the comparison of samples melting profile with melting profiles from known methylation 
standards, the methylation percentage of samples can be determined (150).  
To evaluate methylation in the APP and ApoE genes MS-HRM was used as an alternative 
approach. In order to achieve better analysis through MS-HRM due to excessive number of CpGs 
sites, the APP gene sequence amplified before, was divided into two small fragments with 223bp 
and 236bp in length that were amplified using the primers listed in Table 9. On the other hand, as 
ApoE did not contain so many CpG sites, the same primers used in section 3.7.1 were also used. 
Table 9 – Primers used in MS-HRM for methylation analysis of ApoE and APP. 
Gene Primer sequence 
Annealing 
Temperature (°C) 
PCR product 
length (bp) 
ApoE 
Fw1: 5' GGGTAGGGGGAGAATAGTTTAT 3' 
62 403 
Rv1: 5' CTTACATCCCAATCCAACTACT 3' 
APP 
Fw1: 5' TGGTTTTAGATTTTTTTTTTTATTGT 3' 
61 223 
Rv1: 5' AACCAAACRAATCAACTAATCC 3' 
Fw2: 5' GGTGGGTYGGATTAGTTGAT 3' 
62 236 
Rv2: 5' CCAACAAAAACAATACCAAACC 3' 
The methylation percentages can be easily accessed through comparison with a standard 
curve with defined methylation ratios. The different methylation percentages were prepared by 
mixing methylation controls from CpGenome™ Human Methylated & Non-Methylated DNA 
Standard Set (Millipore) in different ratios. To generate the standard curve the methylation 
percentages used were: 0; 1; 2; 5; 10; 25; 50 and 100. All standards and samples underwent 
bisulfite modification at the same time and conditions. The PCR reaction was prepared according 
to Table 10 and all samples, along with standards, were run in duplicates applying the PCR 
program listed in Table 11, using StepOnePlus Real-Time PCR System (Applied Biosystems). 
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Table 10 – PCR reaction for real-time amplification. 
Components Volume/reaction (μl) 
bDNA (≈20ng/μL) 2 
MeltDoctor™ HRM Master Mix 10 
Primer Fw (5μM) 1.2 
Primer Rv (5μM) 1.2 
Nuclease free water 5.6 
Total 20 
Table 11 – MS-HRM PCR program. 
Number of cycles Step Temperature (°C) Duration 
1 Initial denaturation 95 10 min 
40 
Denaturation 95 15 sec 
Annealing/Extension 
Primer Tm 
(see Table 9) 
1:30 min 
1 Melt curve 
95 10 sec 
60 1 min 
60 / 95 - 
3.8.1. High Resolution Melting (HRM) analysis 
The methylation of samples was evaluated comparing the melt curve pattern of standard, 
using High Resolution Melt (HRM) Software v3.0.1. Before determining methylation percentages, 
amplification plots and melt curves of all samples and standards were analyzed to assure PCR 
specificity.  
3.9. DIRECT BISULFITE SEQUENCING 
PCR products of ApoE gene were generated as detailed in section 3.7.1. The purification 
of PCR products was done using QIAquick PCR Purification Kit (Qiagen), according to 
manufactures instructions. Buffer PBI was added to PCR products in a ratio of 1:5 and then 
applied to the spin columns. The columns were then centrifuged at 10000 xg during 1 min. After, 
Buffer PE was added to the columns and then centrifuged in the same conditions. In order to 
DNA methylation as a potential biomarker for Alzheimer Disease 
 
43 
 
obtain PCR products with high levels of purity, another centrifugation step was performed. The 
elution of DNA from columns was carried out using 30μl of Mili-Q water, incubation 5min at room 
temperature and then centrifuged at 10000 xg for 1min. The purity and concentration of PCR 
products was evaluated using NanoDrop Spectrophotometer ND-1000 (Thermo Scientific). 
For the sequencing reaction, 3 ng of PCR products was used along with an internal reverse 
primer (sequence: 5’ CCAACTCTTTCTAAAAACCCCT 3’), under PCR conditions present in the Table 
12. The DNA was precipitated by adding sodium acetate (3M, pH 5.2) and absolute ethanol in a  
1:10 and 2.5:1 ratio, respectively; vortexed and incubated for 15min at room temperature. After, 
the samples were centrifuged at 14000rpm for 20min. The pellet was then washed with 250μl of 
70% ethanol and centrifuged at 14000rpm for 5min. The supernatant was removed and dried at 
37°C for approximately 1 hour, and the ressuspended in 20μl of formamide. 
The samples were applied in ABI PRISM™ Genetic Analyzer 310 (Applied Biosystems) and 
the results were analyzed using Sequence Scanner 2 (Applied Biosystems) and BiQ Analyzer 
(available in http://biq-analyzer.bioinf.mpi-inf.mpg.de/index.php). 
Table 12 - PCR conditions for PCR sequencing reaction. 
Number of cycles Step Temperature (°C) Duration 
1 Initial denaturation 96 1 min 
25 
Denaturation 96 30 sec 
Annealing 42 15 sec 
Extension 60 4 min 
 
For qualitative analysis, CpG with 20% or lower were considered unmethylated, and CpG 
with methylation percentage above it were treated as methylated (partially methylated between 
20%-80%; and above 80% considered methylated). On the other hand, for quantitative analysis of 
CpG sites, the methylation percentages of each were calculated according with the following 
equation (151): 
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4.1. GENOMIC DNA EXTRACTION FROM WHOLE BLOOD SAMPLES  
Genomic DNA extraction of all samples was carried out as described in section 3.2. Upon 
extraction, the purity and concentration of DNA samples was determined using a NanoDrop 
spectrophotometer. Genomic DNA samples exhibited 260/280 ratios between 1,70 and 1,89; and 
concentrations that ranged from 27,6 ng/μl to 51,5 ng/μl (Table 13). Concentrations were within 
the expected values, which were 30-60 ng/μl according to the manufacture instructions. 
Table 13 - NanoDrop results of samples genomic DNA.  
Condition COD Age 
260/280 
Ratio 
DNA 
Concentratio
n 
(ng/l) 
Age- and Sex- 
Matched Controls 
C1 49 1,89 50,5 
C2 72 1,87 28,6 
C2’ 72 1,85 39,2 
C3* 75 1,86 36,4 
C7 78 1,86 51,5 
C8 74 1,81 31,0 
C9 82 1,80 51,5 
Possible AD Patients 
D1 49 1,78 37,9 
D2* 72 1,86 35,7 
D3 74 1,79 36,1 
D4 74 1,79 48,6 
D5 76 1,88 30,2 
D6 76 1,70 34,4 
D7 80 1,81 52,3 
D8 74 1,84 27,6 
D9 83 1,81 40,2 
Internal Positive 
Control 
IPC 78 1,84 46,3 
In all samples the DNA did not show signs of degradation and bands intensity were in 
general proportional to genomic DNA concentration determined (Figure 15). The gDNA yield 
correlates with the number of white blood cells, which may vary among individuals according to 
* C3 was the age- and sex-matched control for patients D3-D6. D2 has 2 controls (C2 and C2´). 
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age, sex and immune system, among other factors, thus explaining the different concentrations 
obtained. 
 
Figure 15 - Genomic DNA agarose gel electrophoresis. Samples were loaded in a 1% agarose gel.  
 
4.2. GLOBAL METHYLATION LEVELS IN AD PATIENTS  
The global methylation levels of samples were determined using an ELISA-based assay. As 
expected the levels of methylation were very low, ranging from 0,3 % to 1,1%. In general, the 
global methylation levels mean of AD patients were lower when compared to age- and sex-
matched controls (0,75% (±0,29) vs 0,86% (±0,29)) (Figure 16). The only exceptions were the 
patients D2 and D9. Although no clear correlation could be observed between age and the 
methylation levels in the study group, these results point to a global hypomethylation in possible 
AD patients, relatively to age- and sex-matched control individuals.  
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Figure 16 - Dispersion graphic of global methylation percentages of possible AD patients and age- and sex-matched 
controls. The blue and red dashed lines represent the mean of global methylation levels for possible AD patients and 
age- and sex-matched controls, respectively. The pairs C8-D8 and C9-D9 are males while the other samples are females. 
Controls and patients were age- and sex- matched (table 15).  
 
4.3. METHYLATION LEVELS IN AD ASSOCIATED GENES 
Different approaches were used to evaluate the methylation of promoter regions in APP 
and ApoE genes, the PCR amplification of the region followed by enzyme restriction, the MS-HRM 
and bisulfite direct sequencing. As methylated and unmethylated strands amplify better at 
different temperatures, methylated and unmethylated DNA controls were tested to determine 
the temperature in which both strands amplify at similar proportions. MS-HRM was also 
optimized using methylated and unmethylated DNA controls. The reaction was considered to be 
optimized when both methylated and unmethylated strands amplified at equal proportions 
(optimal PCR conditions were described in M&M section).  
4.3.1. Restriction pattern of APP and ApoE genes in AD patients 
To evaluate if the restriction pattern of promoter regions were different among control 
and disease patients, the DNA was first bisulfite modified and then amplified for the regions of 
interest. Both genes were successfully amplified and the expected product size of 403bp for ApoE 
and 434bp for APP obtained for all samples (Figure 17 and Figure 18). 
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Figure 17 - ApoE promoter sequence amplified by PCR. All samples were successfully amplified and the 403bp fragment 
obtained. Along with the aged- and sex-matched controls, an IPC sample was included. 
In the case of APP gene, two samples (D1 and D2) showed a slightly lower DNA size band 
than expected, probably due to a problem during the gel preparation or due to excessive loading 
dyes. Nonetheless both samples, similarly to the others, exhibited the same DNA size after 
restriction digestion, indicating that the fragment was correctly amplified. 
 
Figure 18 - APP promoter sequence amplified by PCR. All samples were successfully amplified and the expected size 
fragment of 434bp obtained. Along with the aged- and sex-matched controls, an IPC and a 100% Methylated DNA 
Control (MC), were included. 
Following PCR amplification the resulting fragments were incubated with different 
restriction enzymes in order to obtain a restriction pattern (COBRA) of samples. The evaluation of 
the efficiency of the restriction digestion reaction was done by using a methylated DNA control, in 
which all cleavage sites are methylated. For this control all the expected DNA fragments, after 
digestion, were visible, both for ApoE and APP gene as explained in Figure 13 and Figure 14 
(section 3.7.2).   
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Under these conditions no distinct pattern was observed that could differentiate AD 
patients from age- and sex-matched controls, with both groups exhibiting heterogeneous 
methylation levels (Figure 19). 
 
 
Figure 19 - Electrophoretic analysis of ApoE promoter sequence restriction by SsiI. All samples exhibited good 
amplification signals and no distinct pattern could be observed among groups for the region in study. Along with the 
study group samples, an internal positive control (IPC) and a 100% Methylated DNA Control (MC) were included. 
For APP gene, no methylation could be observed neither for AD patients nor age- and sex-
matched controls, as all fragments have approximately the entire DNA fragment size. The two 
bands of approximately 70bp and 50bp, present in all samples, correspond to non-specific 
product since no intermediate bands was seen, suggesting the inexistence of methylation for the 
APP region in study (Figure 20).  
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Figure 20 - Electrophoretic analysis of APP promoter sequence restriction by Hhal. All samples showed a good 
amplification signals nonetheless no restriction pattern could be observed, indicating the absence of methylation in the 
enzyme recognition sites of this promoter region. The two bands with lowest size are unspecific products. 
4.3.2. Evaluation of ApoE and APP methylation levels by MS-HRM 
Using MS-HRM technique the ApoE promoter region was successfully amplified for all 
cases, nonetheless, and contrary to what was expected both unmethylated and methylated DNA 
controls exhibited similar methylation levels (verified by sequencing) for this region, therefore it 
was not possible to prepare standards to determine the precise methylation levels of each 
sample. Although a quantitative assay was not viable, by comparing the melting curves using HRM 
software (Figure 21) it was possible to group the samples into two variants (Table 14). However, 
these two variant groups contained both AD patients and controls, not allowing their distinction, 
at least for the ApoE regions evaluated using this approach.  
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Figure 21 – HRM curve generated by amplification of ApoE gene. A – Amplification plot for samples and methylation 
DNA controls with each color corresponding to a sample. B – Aligned melt curves between 74,0°C and 81,5°C with 
samples grouped by variants according with the similar melting behavior.; C – Derivative melt curves exhibiting the 
amplification of only one fragment with low differences melting temperatures due to the presence of a single peak in 
each sample, controls and DNA methylation control. No distinct profile could be observed with both possible AD 
patients and age- and sex-matched controls localized in the same variants (detailed in table 14). 
As APP promoter gene region had many CpG sites, this region was amplified using two 
different sets of primers and independently PCR conditions, which amplified the region upstream 
(Figure 22) and downstream (Figure 23) of the TSS. In both cases, the samples showed identical 
melting profiles indicating similar levels of methylation. Unexpectedly, the unmethylated DNA 
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control exhibited methylation levels above samples, indicating that for the region in study this 
control in at least in part methylated, thus not representing a real unmethylated control. 
 
Figure 22 – HRM curve generated by amplification of APP region upstream TSS (first primer set). A – Amplification plot 
for samples and methylation DNA controls with each color corresponding to a sample. B – Aligned melt curve between 
77,9°C and 89,5°C with samples grouped by variants according with the similar melting behavior ; C – Derivative melt 
curves showing two main peaks at 81°C and 87,5°C that correspond to unmethylated and methylated DNA fragment 
population, respectively. No distinct profile could be observed as both possible AD patients and age- and sex-matched 
controls were localized in the same variants.(detailed in table 14). 
DNA methylation as a potential biomarker for Alzheimer Disease 
 
55 
 
 
Figure 23 - HRM curve generated by amplification of APP region downstream TSS (second primer set). A – Amplification 
plot for samples and methylation DNA controls with each color corresponding to a sample. B – Aligned melt curve 
between 79°C and 89,8°C with samples grouped by variants according with similar melting behavior; C – Derivative melt 
curves showing three main peaks at 77°C, 80°C and 87,5°C, however only the last two having relevance to the study and 
corresponding to unmethylated and methylated DNA fragment population, respectively. The first peak may result from 
unspecfic product generated in the PCR reaction. No distinction could be observed as both possible AD patients and 
age- and sex-matched controls localized in the same variants (in detailed at Table 14). 
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The results of variant calls obtained for HRM are listed in the Table 14. Samples were 
grouped in each variant according to the similarity of melting profiles. Using this approach no 
distinction could be made between control and possible AD individuals for the APP promoter 
regions evaluated.  
Table 14 – Variant call results from HRM analysis. The Silhouette Scores helped software to determine the variants and 
it measures the level of sample similarity in each variant according to the melting profile. Samples with similar melting 
profiles were grouped into the same variant. 
 
4.3.3. Evaluation of ApoE methylation levels by sequencing analysis  
Since no differences could be observed for the APP promoter region chosen, this 
approach was only carried out for ApoE gene, which revealed minor modifications by COBRA 
assay. In order to set up the optimal conditions for PCR products, the methylated and 
unmethylated DNA controls were initially sequenced. After establishing the optimal sequencing 
conditions, all PCR products were sequenced and analyzed. In all samples, whole methylation 
percentages for the promoter sequence of ApoE were determined, as well as methylation 
upstream and downstream the TSS. Furthermore, for each sequence the bisulfite conversion 
efficiency were evaluated, ensuring that all non-methylated cytosines had been converted and 
ensuring that all sequences could be used for analysis. 
 
Gene Variant Samples 
Silhouette 
Scores 
ApoE 
1 
Standards 0% methylated 
80,0-99,8 
Samples D4, C8, C9, D1, C2’, D3, D5, D6, D9 and IPC  
2 Samples C1, C2, C3, C7, D2, D7 and D8  
3 Samples 100% methylated 
 
APP 
(upstream) 
1 Standards 0%, 1%, 3%, 5%  
84,0-98,8 2 Samples All the samples tested 
3 Standards 10%, 25%, 100% 
APP 
(Downstream) 
1 Samples All the samples tested 
84,0 – 98,8 
2 Standards 0%, 1%, 3%, 5% 
3 Standards 10%, 25% 
4 Standards 100% 
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Although for the ApoE amplified sequence the methylated DNA control had all CpG sites 
methylated (Figure 24), unmethylated DNA control exhibited almost equal levels of methylation 
as the methylated one (Figure 25), which can also explain the results obtain in MS-HRM analysis 
(Figure 21). 
 
Figure 24 – ApoE bisulfite sequencing of methylated DNA control. The sequence represents part of the gene sequence 
in study (between position –95 and –30 from the TSS). Throughout the bisulfite sequencing, it was possible to observe 
that all non-methylated cytosines were successfully converted to uracil and that all CpG sites were methylated. 
 
Figure 25 – ApoE bisulfite sequencing of unmethylated DNA control. The sequence represents part of the gene 
sequence in study (between position –55 and –3 according with the TSS). Throughout the bisulfite sequencing, all non-
methylated cytosines were successfully converted to uracil. However, CpG sites appeared methylated or 50% 
methylated indicating that the control is not a true unmethylated control for ApoE promoter gene. 
The samples were sequenced in the same conditions as the methylation DNA controls but 
only five samples managed to reach to the end of sequence. All the other samples showed many 
signal interference that did not allow the electropherogram analysis. Nonetheless, it was possible 
to sequence the ApoE region upstream TSS (Figure 26) for all samples, which include the first 6 
CpGs. Qualitative analyses revealed that samples, as already observed in HRM analysis, exhibited 
low methylation levels, in general below 20% (Figure 26).  
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Figure 26 - Results from bisulfite sequencing of APoE upstream TSS region. All circles represent CpG sites in the 
sequence. Black circles are methylated CpG, half black and half white circles represent partially methylated CpGs; and 
white ones represent unmethylated CpG.sites. 
The semi-quantitative analysis revealed variability between AD patients and age- and sex-
matched controls, suggesting, as the techniques used before, that there is not an evident ApoE 
methylation pattern typical of AD patients, at least for the region tested (Table 15). However, and 
although no clear differences could be observed in the global CpGs methylation levels for this 
region among age- and sex-matched controls and possible AD individuals (25% versus 28%, 
respectively), differences were detected if we look at the mean values at specific CpG sites. In 
particular, a tendency to a methylation increase for CpG1, 3 and 5 sites and a marked methylation 
decrease for CpG6 could be observed for possible AD patients comparatively to control 
individuals. 
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Table 15 – Semi-quantitative analysis of CpG sites upstream ApoE TSS. The CpG 1, CpG3 and CpG 5 show a tendency for 
increased methylation level in possible AD patients. On the other hand, CpG 6 exhibited the opposite behavior, with 
possible AD patients showing increased methylation levels when compared to age- and sex-matched controls.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.   
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5. Discussion 
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The DNA methylation is the epigenetic mechanism that has been linked to cancer and 
recently it is being pointed to have an important role in neurological disorders, including AD. As 
AD etiology and pathological development is yet to be clarified, epigenetic mechanisms like DNA 
methylation may underlie the imbalance of protein expression in this disease, such as increase in 
APP and consequently Aβ production, which along with aggregation of other proteins, lead to the 
formation of senile plaques, one of the major hallmarks in AD pathology. 
In this pilot study, global methylation levels were measured through an ELISA assay. The 
global methylation percentages results showed that genomic methylation levels, as expected, are 
very low (below approximately 1%). Global methylation analysis pointed to a hypomethylation in 
AD patients when compared to age- and sex-matched controls, which can explain the abnormal 
expression of certain genes due to disruption of its DNA epigenetic control mechanisms. This 
finding is also in agreement with other studies that report global and gene-specific 
hypomethylation in AD patients (152–154). However, individually some samples exhibited the 
opposite behavior either showing equal or increased methylation levels, which can be explained 
taking into account the clinical history of those patients. The two control-patients pairs that 
exhibited equal levels of methylation (Figure 16) were C3-D6 and C7-D7 (Table 13). The clinical 
history of the patient D6 revealed parkinsonism symptoms and treatment for dizziness. Although 
several studies had reported hypomethylation in Parkinson disease either in brain or blood 
samples (107,155–157), the treatment for dizziness can mask the true methylation levels of the 
sample. In another study (158) from our laboratory, carried on the same samples,  the D6 patient 
was also considered an outlier, since it was the only sample that did not fit into the groups 
generated by multivariate analysis for differentiation of possible AD patients from age- and sex-
matched controls, by spectroscopy analysis. On the other hand, D7, besides undergoing the same 
treatment as C7 for dyslipidemia, had also treatment for hypertension and diabetes. DNA 
methylation role in hypertension is still not clear (159,160) but in diabetes some genes had been 
reported as hypermethylated, such as in the case of type 2 diabetes mellitus, either in tissue or 
blood samples (161,162). These results can explain the equal methylation levels in this control 
and AD patient. The patient D2 had a global methylation level above the control, which can be 
explained by the fact that he was being treated for AD, which by itself could induce an increase in 
the global methylation levels. The patient D9 did not have any history of clinical treatment, unlike 
its age- and sex-matched control, C9, which was being treated for hypertension and dyslipidemia 
and therefore, his “true” methylation levels could be also masked by the treatment. 
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Further, previous studies reported (163–165) that the global methylation levels decreased 
with age however in our study this correlation was not clear most probably due to the study 
group size, which needs to be increased. 
Besides the global methylation analysis two important genes in AD pathology were 
studied in order to search for methylation changes in their promoter region among possible AD 
patients and aged- and sex-matched controls. DNA methylation is inversely correlated with gene 
expression, thus by studying promoter regions, more specifically at TSS region, could give insights 
about the variability of methylation in these areas and its correlation with gene expression. The 
genes studied were APP and ApoE, being that for the former gene, the promoter was localized 
within a CGI, while for the ApoE gene the only CGI was located several bases upstream the 
promoter. Different techniques were used in order to characterize the methylation in the 
promoters regions of these genes.  
The first technique used to evaluate the methylation levels of AD related genes was 
COBRA. The aim was to see if any distinctive pattern was visible between age- and sex-matched 
controls and possible AD patients. For the APP promoter region analyzed no differences in the 
methylation levels could be detected when comparing AD patients with age- and sex-matched 
controls, as no cleavage products was visible in neither of them. This result suggests the absence 
of methylation at the sites recognized by the restriction enzyme. On the other hand, ApoE 
promoter exhibited low methylation levels, which is in agreement with the fact that most of the 
PCR product remained uncutted. The detected methylation pattern was very heterogeneous 
between age- and sex-matched controls and possible AD patients, with multiple cleavage patterns 
being detected (Figure 14). This heterogeneity had been also reported by Wang S-C et al (101) for 
the same ApoE promoter region herein tested. In the later study a different ApoE region was also 
evaluated and interindividual epigenetic variability was evident. 
For ApoE promoter gene (Figure 21), MS-HRM experiments used the same set of primers 
used in COBRA, however, some limitations arise due to the lack of adequate controls. The DNA 
methylated and unmethylated controls did not allow a correct interpretation of the melting 
curves since they either had no difference in the melting profile (in the case of ApoE study) or had 
methylation profiles that do not correspond to true unmethylated and methylated DNA controls 
(in the case of APP study). Three different DNA methylation controls under different PCR 
conditions were tested without any satisfactory results. Although the lack of the appropriate 
controls, the melting curve analysis for ApoE promoter allowed grouping the samples into two 
variants with different methylation levels (Table 14). Nonetheless, as both variants contained age 
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and sex-matched controls and possible AD patients no distinct pattern could be identified for 
those. These results corroborate the ones observed in COBRA assay and suggest a methylation 
heterogeneity in this promoter region of the gene. The same was observed for APP MS-HRM 
analysis. All samples exhibited melting curve profiles that indicated levels of methylation below 
the unmethylated control used, hindering the quantification of samples’ methylation levels. 
However, despite being grouped in the same variant in both regions, upstream and downstream 
the APP TSS, samples exhibited slightly different melting profiles that suggest low methylation 
levels that could be correctly quantified by using an appropriate DNA methylation control. 
Furthermore, in the APP derivative melt curve it is possible to view unspecific products in both 
experiences (Figure 22–C and Figure 23–C) with the early appearance of multiple temperature 
melting peaks, indicating that the reaction was not fully optimized. Due to that the melting curve 
behavior of the samples may vary therefore not allowing the correct analysis by this technique. 
Thus far, no study had performed MS-HRM for analysis neither for APP nor ApoE promoter genes. 
Some studies had pointed to an epigenetic regulation of APP expression (166) with some authors 
reporting hypomethylation in different gene regions such as promoter (167) and exonic (116) 
regions; while others reported low methylation levels in APP promoter region, with no differences 
between patients and controls (168). 
In contrast with APP, the ApoE gene exhibited minor alterations in methylation levels 
among controls and patients by COBRA, although their distribution patterns were heterogeneous 
among samples. Hence, in order to determine if any particular CpG site of ApoE promoter region 
(not possible through COBRA or MS-HRM) was differently methylated in age- and sex-matched 
controls and possible AD patients, Bisulfite Direct Sequencing, considered the gold-standard for 
methylation analysis, was carried out. The amplification of ApoE for this analysis was successful. 
Of the total CpG sites, six could be analyzed for all samples when using the reverse internal 
primer. Analyzing global CpG methylation levels, no differences were observed and the results 
correlated with the ones verified in MS-HRM. However, comparing the mean levels of controls 
and possible AD patients, some differences were detected in specific CpG sites (Table 15). In 
particular, CpG 1, 3 and 5 appeared to show a tendency to be more methylated in AD 
comparatively to age- and sex-matched controls. On the other hand, CpG 6 showed a decrease in 
methylation levels for possible AD patients. It would be interesting to confirm these results in a 
large sample number and to extend this analysis to the 15 CpG sites of ApoE promoter region.  
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CONCLUDING REMARKS 
In this study a tendency for a global methylation decrease of possible AD patients was 
observed when compared to aged- and sex-matched controls. In particular, when addressing the 
methylation levels of APP, a gene linked to AD pathology, and ApoE, described as a risk factor to 
AD, no gene specific methylation differences could be observed between possible AD patients and 
control individuals, either by COBRA or MS-HRM. However, when looking at specific CpG sites of 
ApoE promoter region by sequencing analysis differences could be detected between age- and 
sex-matched controls and possible AD patients. Since gene expression can be regulated by 
epigenetic mechanisms, alterations in the methylation levels may render in imbalanced 
expression of genes relevant to AD pathology. 
STUDIED LIMITATIONS AND FUTURE PERSPECTIVE 
The first limitation of this study is related with the number of samples used (below 30). 
The results obtained for global methylation needs to be confirmed using a large number of 
samples, including the ones used in this study.  
Another important issue lies on the fact that the DNA methylation controls were not the 
appropriate for MS-HRM analysis and, therefore, could induced bias in the PCR amplification, 
resulting in inaccurate estimation of methylation levels in COBRA and in bisulfite sequencing 
(169). In order to address this issue, DNA used should be from a cellular lineage with APP and 
ApoE genes unmethylated. The results from APP MS-HRM analysis revealed unspecific products 
that could affect the melting profile of the samples. For the region before APP TSS, different 
conditions were tested but unspecific products had been a constant in every assay. Probably a 
new set of primers for the same region could yield better results. The same solution could 
improve the results for the region downstream APP TSS. 
In the case of bisulfite sequencing, the use of M13-tailed primers can be a solution to 
obtain ApoE complete sequencing in all samples and to analyze the 15 CpGs sites. Furthermore, 
all samples exhibit some guanine base signal background that could culminate in bias methylation 
levels. Therefore, the results from bisulfite sequencing need to be confirmed using a different 
basecaller, such as KB basecaller (Applied Biosystems), which is indicated for bisulfite sequencing 
analysis. This software was incompatibility to Genetic Analyzer 310 platforms. Furthermore, the 
results obtained using reverse primer should also be confirmed using forward primer. 
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Furthermore, in future studies, the methylation levels of other CGI in APP and ApoE 
genes, both upstream from the respective promoters, could be evaluated in order to determine if 
the methylation levels are altered and could have any influence in its gene expression. 
Furthermore, there are others AD-related genes that may hold interest in evaluate the 
methylation profile. The genes of presenilin 1 and 2 and MAPT gene, which encodes tau protein, 
one of the major components in the NFTs, can give more insights and help in understanding of the 
epigenetic changes in AD pathology.  
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This section presents the equipment and composition of solutions used for the different 
techniques applied. 
I. Genomic DNA Extraction 
a. Equipment 
i. Centrifuge 5417R (Eppendorf) 
ii. Thermomixer comfort (Eppendorf) 
b. Reagents 
i. QIAamp DNA Blood Mini Kit (Qiagen) 
ii. RNase A (Sigma-Aldrich 
II. Bisulfite DNA modification 
a. Equipment 
i. Centrifuge 5417R (Eppendorf) 
ii. My Cycler TM (Bio-Rad) 
b. Reagents 
i. EZ DNA Methylation-Gold Kit (Zymo Research) 
III. Global methylation analysis 
a. Equipment 
i. Infinite M200 (TECAN) 
b. Reagents 
i. Methylated Quantification Kit (Abnova) 
IV. COBRA 
a. Equipment 
i. My Cycler TM (Bio-Rad) 
ii. DNA electrophoresis system (Bio-Rad) 
iii. Power PAC300 (Bio-Rad) 
iv. Gel Doc XR System (Bio-Rad). 
b. Reagents 
i. Maxima Hot Start Master Mix (Thermo Scientific) 
ii. KAPA HiFi Uracil+  Master Mix(GRISP) 
iii. HhaI (Thermo Scientific) 
iv. SsiI (Thermo Scientific) 
v. 10x Buffer Tango (Thermo Scientific) 
vi. 10x Buffer O (Thermo Scientific) 
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vii. Agarose (Eurobio) 
viii. GreenSafe (NZYTech) 
ix. 0,5M Ethylenediamine tetra-acetic acid (EDTA) (pH 8.0) 
1. To 200ml of deionized H2O add: 
a. 46,52g EDTA 
2. Mix until the solute has dissolved and adjust pH to 8.0 
using NaOH. 
3. Adjust the volume to 250ml with deionized H2O. 
4. Autoclave solution. 
x. 50x Tris-Acetate-EDTA (TAE) Buffer 
1. To 600 ml of deionized H2O add 
a. 242g Tris Base 
b. 57,1ml Glacial Acetic Acid 
c. 100ml 0,5M EDTA (pH 8.0) 
2. Mix until homogenous solution and adjust the volume to 
1L with deionized H2O. Store at room temperature. 
xi. 1 Kb plus DNA ladder (Invitrogen) 
xii. GRS Low Range Ladder (GRISP) 
xiii. SGTB Buffer (GRISP) 
V. MS-HRM 
a. Equipment 
i. StepOnePlus Real-Time PCR System (Applied Biosystems) 
b. Software 
i. Methyl Primer Express V1.0 
ii. StepOne Software V2.2.2 
iii. High Resolution Melt Software v3.0.1 (Applied Biosystems) 
c. Reagents 
i. MeltDoctor™ HRM Master Mix (Life Techonologies) 
ii. CpGenome™ Human Methylated & Non-Methylated DNA 
Standard Set 
VI. Direct Bisulfite Sequencing 
a. Equipment 
i. ABI PRISM™ Genetic Analyzer 310  
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b. Software 
i. Sequencing Analysis Software V 3.4.1 
ii. Sequence Scanner 2 
c. Reagents 
i. QIAquick PCR purification 
ii. Ethanol 100%  
iii. Ethanol 70% 
iv. sodium acetate 3M pH 5.2 
 
